Semaglutide 910463-68-2

99% up by HPLC for injection grade; 98% up by HPLC for oral grade

Product categories

New Products

Product Details

Product Information

Product name	Semaglutide
CAS No.	910463-68-2
Sequence	H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys[(AEEA)2-γ-Glu-N-(17-carboxy-1-oxoheptadecyl)]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Molecular Formula	C187H291N45O59
Molecular Weight	4113.57754
Purity	99% up by HPLC for injection grade 98% up by HPLC for oral grade
Appearance	White powder

Usage

Highlight of our semaglutide

1) Commercial production 10kg/month , 1kg in stock

2) With USDMF for Sermaglutide API.

3) Produced in GMP condition workshop, with:

Injection grade, purity 99% up by HPLC;

Oral grade, purity 98% up by HPLC

4) Competitive price

5) Using advanced recombinant protease with Bio-enzyme technology to produce the intermediates of Sermaglutide (main chain and side chain).

Semaglutide Intermediates:

(1) Main Chain: GLP-1 (9-37), CAS No.: 1169630-82-3, 95% up by HPLC

(2) Side Chain:

tBuO-Ste-Glu(AEEA-AEEA-OH-OtBu CAS No.: 1118767-16-0, 98% up by HPLC

Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEAI-OH CAS No.:1662688-20-1 , 98% up by HPLC

(3) Molecular Blocks

Octadecanedioic Acid Mono-tert-butyl Ester

CAS No.: 843666-40-0, 98% up by HPLC
AEEA-OH-HQ   CAS No.: 134979-01-4, 98% up by HPLC
Fmoc-AEEA-OH CAS No.: 166108-71-0, 98% up by HPLC
Boc-AEEA-OH CAS No.: 108466-89-3, 98% up by HPLC
Fmoc-AEEA-AEEA-OH CAS No.: 560088-89-3, 98% up by HPLC
AEEA-AEEA-OH CAS No.: 1143516-05-5, 98% up by HPLC
Boc-Hs( Trt)-Aib-OH   CAS No.: 2061897-68-3, 99% up by HPLC
Fmoc-Glu(OtBu)-Gly-OH CAS No.: 866044-63-5, 99.5% up by HPLC
Boc-His(Eoc)-Aib-Glu(OtBu)-Gly-OH   CAS No.: 1169630-31-2, 98% up by HPLC

Function of Semaglutide

Semeglutide is a long-acting glucagon-like peptide 1 (GLP-1) analog, a GLP-1 receptor agonist, and has potential therapeutic efficacy in type II diabetes mellitus (T2DM).

Compared with liraglutide, semaglutide has a longer aliphatic chain and increased hydrophobicity, but semaglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only bind closely to albumin, cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.

Hot Tags : Semaglutide Semaglutide API Semaglutide peptide Semaglutide side chain Semaglutide main chain Semaglutide intermediate

Send A Message

Related Products

Liraglutide 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.